Supplementary Table S9 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table 9. CyTOF antibody panel for PBMC, BMMC, and tumor-infiltrating immune cells, relevant to Supplementary Figure 10.
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416628763
Cites:
Cited by:
Related to: